GlassScriptPhysician profile
Rebecca Rivera
NPI 1033129952
$1,190.93
in general payments reported to CMS, 2019-2025
23 companies · $317 in 2025
The $317 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $8.59 · 2021: $77.79 · 2022: $214 · 2023: $204 · 2024: $370 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $890.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $199.51 | 2023-2025 | Closurefast, Kyphon Express II Kyphopak Tray, Intellis Adaptivestim |
| Hologic Sales and Service, LLC | $198.49 | 2020-2025 | Acessa Provu System, Myosure Tissue Removal Device |
| Novo Nordisk INC | $104.77 | 2024 | Wegovy |
| Nevro Corp. | $95.03 | 2022 | |
| Smith+Nephew, INC. | $77.12 | 2025 | Stravix Pl |
| Ethicon US, LLC | $61.81 | 2021-2024 | Ethicon, Enseal |
| Sage Therapeutics, LLC | $47.57 | 2024-2025 | Zurzuvae |
| Pfizer INC. | $44.31 | 2024-2025 | |
| Boston Scientific Corporation | $41.42 | 2024 | |
| Organon LLC | $40.43 | 2021-2025 | Nexplanon |
| Vertex Pharmaceuticals Incorporated | $33.18 | 2025 | |
| Abbvie INC. | $28.93 | 2023 | Lo Loestrin Fe, Orilissa |
| Genmab U.S., INC. | $25.73 | 2023 | Epkinly |
| Phathom Pharmaceuticals, INC. | $24.94 | 2025 | Voquezna |
| Dynavax Technologies Corporation | $24.54 | 2023 | Heplisav-B |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.21 | 2024 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $23.11 | 2023 | |
| Janssen Biotech, INC. | $21.93 | 2024 | Tremfya |
| Lilly USA, LLC | $19.74 | 2024 | Zepbound |
| Orthofix Medical, INC. | $16.49 | 2024 | Spinal-Stim |
| Astellas Pharma US INC | $13.82 | 2024 | Veozah |
| Daiichi Sankyo INC. | $13.65 | 2024 | Injectafer |
| Merck Sharp & Dohme LLC | $11.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebecca Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.